Logo

MYO

Myomo, Inc.

MYO

Myomo, Inc. • NYSE
$0.88 ▲ 2.43% (+0.02)
Market Cap $33.95 M
52w High $7.17
52w Low $0.71
Dividend Yield 0%
P/E -3.16
Volume 576.05K
Outstanding Shares 38.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $10.091M ▲ $9.96M ▼ $-3.663M ▲ -36.3% ▲ $-0.09 ▲ $-3.083M ▲
Q2-2025 $9.652M ▼ $10.642M ▲ $-4.632M ▼ -47.989% ▼ $-0.11 ▼ $-4.162M ▼
Q1-2025 $9.832M ▼ $10.13M ▲ $-3.465M ▼ -35.243% ▼ $-0.084 ▼ $-3.073M ▼
Q4-2024 $12.068M ▲ $8.861M ▲ $-260.081K ▲ -2.155% ▲ $-0.007 ▲ $220.719K ▲
Q3-2024 $9.208M $7.903M $-966.409K -10.496% $-0.025 $-836.335K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.554M ▼ $34.077M ▼ $19.452M ▼ $14.626M ▼
Q2-2025 $15.482M ▼ $38.672M ▼ $21.057M ▲ $17.615M ▼
Q1-2025 $21.524M ▼ $40.867M ▼ $19.18M ▲ $21.687M ▼
Q4-2024 $24.865M ▲ $42.244M ▲ $17.53M ▲ $24.714M ▲
Q3-2024 $6.623M $16.313M $7.021M $9.292M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.663M ▲ $-1.829M ▲ $189.698K ▲ $-50K ▼ $-1.687M ▲ $-2.882M ▲
Q2-2025 $-4.632M ▼ $-8.865M ▼ $-757.348K ▲ $4M ▲ $-5.553M ▼ $-10.123M ▼
Q1-2025 $-3.465M ▼ $-2.677M ▼ $-1.896M ▼ $-36.506K ▼ $-4.579M ▼ $-3.348M ▼
Q4-2024 $-260.081K ▲ $3.366M ▲ $-1.353M ▼ $15.77M ▲ $17.75M ▲ $2.505M ▲
Q3-2024 $-966.409K $-1.494M $2.825M $-199.5K $1.152M $-1.815M

Revenue by Products

Product Q2-2024Q3-2024Q4-2024Q1-2025
Product
Product
 $10.00M ▲$10.00M ▲$20.00M ▲$10.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Myomo is still a very small, early-stage commercial business. Revenue has been inching higher over the last five years, but it is starting from a very low base. The company has been consistently losing money, with operating and net losses each year. On the positive side, gross profit has improved as sales have grown, suggesting the basic product economics are getting better. However, the business is not yet large enough to cover its operating costs, so profitability remains a future goal rather than a current reality.

Balance Sheet

Balance Sheet The balance sheet is lean but relatively simple. Assets are modest and heavily concentrated in cash, which provides some short-term flexibility. Debt has only recently appeared and is still limited, so the company is not highly leveraged. Equity has been positive throughout, but at a small scale, reflecting a business that is still in a build-out stage rather than a mature, capital-heavy company. Overall, the balance sheet looks more like that of a young, growing medical device firm than a fully scaled operator.

Cash Flow

Cash Flow Cash flow from operations has historically been negative, reflecting recurring losses and the investment needed to grow. More recently, operating cash flow has moved closer to break-even, which is an encouraging sign of improving efficiency and scale. Capital spending has been light, so free cash flow has mainly been driven by operating performance rather than big equipment or facility investments. The key question going forward is whether rising revenues and better margins can consistently pull cash flow into positive territory before additional funding is needed.

Competitive Edge

Competitive Edge Myomo operates in a narrow but important niche: powered upper-limb orthoses for people with limited arm and hand function. It benefits from being an early mover with a specialized focus, backed by a substantial patent portfolio that runs well into the next decade. Its MyoPro product line is supported by FDA registration and clinical evidence, which together form a meaningful barrier for new entrants. A major strength is its know-how in navigating U.S. reimbursement and billing insurers directly, something many small device companies struggle with. In addition, Myomo is building a growing network of orthotics and prosthetics clinics, which can deepen relationships with clinicians and create repeat demand. Competition exists, especially from European players, but Myomo’s combination of technology, reimbursement expertise, and ecosystem of services gives it a credible, defensible spot in its segment, particularly in the U.S.

Innovation and R&D

Innovation and R&D Innovation is at the core of Myomo’s story. Its technology originated from top-tier research institutions and is protected by a wide set of patents covering the use of myoelectric signals to power upper-limb braces. The company continues to invest in refining its MyoPro devices, focusing on comfort, ease of use, and better integration of commonly needed customizations. It is also building a broader ecosystem of digital tools and services—such as remote therapy support, game-based training, and patient-provider apps—which adds value beyond the hardware itself. Looking ahead, management has flagged a pipeline of next-generation products that would incorporate advances in robotics, software, materials, and artificial intelligence, as well as plans to expand internationally, including in Germany and China. Overall, R&D is not just a cost center here; it is central to the company’s identity and long-term differentiation.

Summary

Myomo is a small but focused medical device company trying to scale a promising, patented technology in a specialized area of wearable robotics. Financially, it is still in a loss-making, early-growth phase, with gradually rising revenue, improving gross profit, but no sustained profitability yet. The balance sheet is relatively straightforward, with a strong cash component and modest debt, typical of a young growth company. Cash flows have been negative but are trending in the right direction as operations become more efficient. Strategically, Myomo’s strength lies in its technological leadership, deep patent protection, early-mover position, and practical expertise in getting insurers—especially Medicare—to pay for its devices. Its ecosystem of services and expanding clinic network further reinforces its position. The main uncertainties revolve around its ability to scale sales as planned, control costs, maintain and expand reimbursement coverage, and successfully enter new international markets while managing its limited financial base. If it can execute on growth and innovation while moving toward consistent positive cash flow, the company could further solidify its niche within medical robotics, but the path remains execution- and funding-sensitive.

NEWS

November 10, 2025 · 4:05 PM UTC

Myomo Reports Third Quarter 2025 Financial and Operating Results

Read more

November 3, 2025 · 4:05 PM UTC

Myomo to Report Third Quarter 2025 Financial Results on November 10

Read more